Immunotherapy

Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
Michael T Serzan, Princy N Kumar, Michael B Atkins

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000898; DOI: 10.1136/jitc-2020-000898
Stromal LAG-3⁺ cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture
Han Zeng, Quan Zhou, Zewei Wang, Hongyu Zhang, Zhaopei Liu, Qiuren Huang, Jiajun Wang, Yuan Chang, Qi Bai, Yu Xia, Yiwei Wang, Le Xu, Bo Dai, Jianming Guo, Li Liu, Yu Zhu, Jiejie Xu

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000651; DOI: 10.1136/jitc-2020-000651
On the mechanism of anti-CD39 immune checkpoint therapy
David Allard, Bertrand Allard, John Stagg

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000186; DOI: 10.1136/jitc-2019-000186
LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
Niklas Klümper, Damian J Ralser, Emma Grace Bawden, Jenny Landsberg, Romina Zarbl, Glen Kristiansen, Marieta Toma, Manuel Ritter, Michael Hölzel, Jörg Ellinger, Dimo Dietrich

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000552; DOI: 10.1136/jitc-2020-000552
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy
Prashant Ramesh Tembhare, Harshini Sriram, Twinkle Khanka, Gaurav Chatterjee, Devasis Panda, Sitaram Ghogale, Yajamanam Badrinath, Nilesh Deshpande, Nikhil V Patkar, Gaurav Narula, Bhausaheb Bagal, Hasmukh Jain, Manju Sengar, Navin Khattry, Shripad Banavali, Sumeet Gujral, Papagudi G Subramanian

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000630; DOI: 10.1136/jitc-2020-000630
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
Jayesh Desai, Sanjeev Deva, Jong Seok Lee, Chia-Chi Lin, Chia-Jui Yen, Yee Chao, Bhumsuk Keam, Michael Jameson, Ming-Mo Hou, Yoon-Koo Kang, Ben Markman, Chang-Hsien Lu, Kun-Ming Rau, Kyung-Hun Lee, Lisa Horvath, Michael Friedlander, Andrew Hill, Shahneen Sandhu, Paula Barlow, Chi-Yuan Wu, Yun Zhang, Liang Liang, John Wu, Virginia Paton, Michael Millward

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000453; DOI: 10.1136/jitc-2019-000453
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
Katsuyuki Hotta, Nobukazu Fujimoto

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000461; DOI: 10.1136/jitc-2019-000461
Master protocols in immuno-oncology: do novel drugs deserve novel designs?
Luca Mazzarella, Stefania Morganti, Antonio Marra, Dario Trapani, Giulia Tini, Piergiuseppe Pelicci, Giuseppe Curigliano

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000475; DOI: 10.1136/jitc-2019-000475
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Jieqiong Liu, Qiang Liu, Ying Li, Qian Li, Fengxi Su, Herui Yao, Shicheng Su, Quanren Wang, Liang Jin, Ying Wang, Wan Yee Lau, Zefei Jiang, Erwei Song

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000696; DOI: 10.1136/jitc-2020-000696
Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses
Victoria A Brentville, Rachael L Metheringham, Ian Daniels, Suha Atabani, Peter Symonds, Katherine W Cook, Mireille Vankemmelbeke, Ruhul Choudhury, Poonam Vaghela, Mohamed Gijon, Ghislaine Meiners, Willem-Jan Krebber, Cornelis J M Melief, Lindy G Durrant

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000560; DOI: 10.1136/jitc-2020-000560

Main menu

Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immunotherapy

Pages